Immodulon links up with myTomorrows over access program

27 June 2019

Privately-held UK biotech Immodulon has teamed up with Dutch firm myTomorrows to develop an Expanded Access Program (EAP) for the unlicensed drug IMM-101.

The immuno-oncology specialist is progressing IMM-101 in a clinical development program as a potential treatment in several cancer settings. The EAP will support the supply in Europe of IMM-101 when prescribed on a named patient basis for those who have no other treatment options.

Steve Glass, chief operating officer of myTomorrows, said: “I am delighted that myTomorrows is to strengthen the relationship with Immodulon. With our unique online platform, combined with our global capabilities of supporting expanded access and real-world data collection, we aim to accelerate access to a medicine in development.”

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK